As we move into the era of individualized cancer treatment, the need for more sophisticated
cancer diagnostics has emerged. Cell-free (cf) nucleic acids (cf-DNA, cf-RNA) and
other cellular nanoparticulates are now considered important and selective biomarkers.
There is great hope that blood-borne cf-nucleic acids can be used for 'liquid biopsies',
replacing more invasive tissue biopsies to analyze cancer mutations and monitor therapy.
Conventional techniques for cf-nucleic acid biomarker isolation from blood are generally
time-consuming, complicated and expensive. They require relatively large blood samples,
which must be processed to serum or plasma before isolation of biomarkers can proceed.
Such cumbersome sample preparation also limits the widespread use of powerful, downstream
genomic analyses, including PCR and DNA sequencing. These limitations also preclude
rapid, point-of-care diagnostic applications. Thus, new technologies that allow rapid
isolation of biomarkers directly from blood will permit seamless sample-to-answer
solutions that enable next-generation point-of-care molecular diagnostics.